Ananth J., Venkatesh R., Burgoyne K., et al. (2002) Atypical antipsychotic drug use diabetes . Psychother Psychosom71: 244-254.
2.
Bell RC, Farmer S., Ries R., et al. (2009) Metabolic risk factors among Medicaid outpatients with schizophrenia receiving second-generation antipsychotics. Psychiatr Serv60: 1686-1689.
3.
Braceland FJ, Meduna LJ and Vaichulis JA ( 1945) Delayed action of insulin in schizophrenia. Am J Psychiatry102: 108-110.
4.
Bresee LC, Majumdar SR, Patten SB, et al. (2010) Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res117: 75-82.
5.
Cohn TA, Remington G., Zipursky RB, et al. (2006) Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report. Can J Psychiatry51: 382-386.
6.
Connolly M. and Kelly C. ( 2005) Lifestyle and physical health in schizophrenia . Adv Psychiatr Treat11: 125-132.
7.
De Hert M., Falissard B., Mauri M., et al. (2008) Epidemiological study for the evaluation of metabolic disorders in patients with schizophrenia: the METEOR study. Eur Neuropsychopharmacol18(Suppl. 4): S444.
8.
De Hert M., Schreurs V., Vancampfort D., et al. (2009) Metabolic syndrome in people with schizophrenia: a review . World J Psychiat8: 15-22.
9.
De Hert M., van Winkel R., Van Eyck D., et al. (2006) Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health2: 14.
10.
Dorland WA ( 2008) Dorland’s Illustrated Medical Dictionary, 28th edition. London: Harcourt Brace & Company, 489-1653.
11.
Fan X., Liu EY, Freudenreich O., et al. (2010) Higher white cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. Schizophr Res , in press.
12.
Fernandez-Egea E., Bernardo M., Donner T., et al. (2009) Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry194: 434-438.
13.
Gianfrancesco F., Pesa J., Wang RH, et al. (2006) Assessment of anti psychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design. Am J Health-System Pharm63: 431-441.
14.
Heila H., Haukka J., Suvisaari J. and Lonnqvist J. ( 2005) Mortality among patients with schizophrenia and reduced psychiatric hospital care. Psychol Med35: 725-732.
15.
Hennekens CH, Hennekens AR, Hollar D. and Casey DE ( 2005) Schizophrenia and increased risks of cardiovascular disease . Am Heart J150: 1115-1121.
16.
Holt RIG and Peveler RC ( 2006) Antipsychotic drugs and diabetes-an application of the Austin Bradford Hill criteria. Diabetologia49: 1467-1476.
17.
Jones DR, Macias C., Barreira PJ, et al. (2004) Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness . Psychiatr Serv55: 1250-1257.
18.
Joukamaa M., Heliovaara M., Knekt P., et al. (2006) Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry18: 122-127.
19.
Kasanin J. ( 1926) The blood sugar curve in mental disease 11. The schizophrenia (dementia praecox group). Arch Neurol Psychiat16: 414-419.
20.
Kolotkin RL, Corey-Lisle PK, Crosby RD, et al. (2008) Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder. Obesity16: 749-754.
21.
Lorenz WF ( 1922) Sugar tolerance in dementia praecox and other mental disorders . Arch Neurol Psychiatry8: 184-196.
22.
Meyer JM, Nasrallah HA, McEvoy JP, et al. (2005) The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res80: 9-18.
23.
Mitchell AJ and Malone D. ( 2006) Physical health and schizophrenia. Curr Opin Psychiatry19: 432-437.
24.
Nikkilä HV, Muller K., Ahokas A., Miettinen K., Rimon R. and Andersson LC ( 1999) Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes. Am J Psychiatry156: 1725-1729.
25.
Oriot P., Feys JL, de Wilmars SM, et al. (2008) Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study . Diabetes Metab34: 490-496.
26.
Potvin S., Stip E., Sepehry AA, Gendron A., Bah R. and Kouassi E. ( 2008) Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry63: 801-808.
27.
Radewiscz K., Garey LJ, Gentleman SM and Reynolds R. ( 2000) Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exp Neurol59: 137-150.
28.
Ryan MC, Collins P. and Thakore JH ( 2003) Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am J Psychiatry160: 284-289.
29.
Saari KM, Lindeman SM, Viilo KM, et al. (2005) A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry66: 559-563.
30.
Saddichha S., Manjunatha N., Ameen S., et al. (2008) Metabolic syndrome in first episode schizophrenia-a randomized double-blind controlled, short-term prospective study. Schizophr Res101: 266-272.
31.
Smith M., Hopkins D., Peveler RC, et al. (2008) First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis . Br J Psychiatry192: 406-411.
32.
Spelman LM, Walsh PI, Sharifi N., et al. (2007) Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabetic Med24: 481-485.
33.
Stober G., Ben-Shachar D., Cardon M., et al. (2009) Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry10: 127-155.
34.
Tarricone I., Gozzi BF, Serretti A., et al. (2010) Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med40: 187-200.
35.
Verma SK, Subramaniam M., Liew A., et al. (2009) Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry70: 997-1000.
36.
Walsh M.-T, Ryan M., Hillman A., et al. (2002) Elevated expression of integrin αIIb βIIIa in drug naive, first episode patients with schizophrenia: preliminary results. Biol Psychiat52: 874-879.
37.
Zhang Z.-J, Yao Z.-J, Liu W., et al. (2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry184: 58-62.
